Nurix's $175M of­fer­ing; In­vivyd CEO is out

Plus, news about Agenus, Ger­resheimer and Oculis:

Nurix Ther­a­peu­tics’ $175M of­fer­ing: The pro­tein de­grad­er biotech up­sized its stock sale, which it will use pri­mar­i­ly to fund stud­ies of its three ear­ly-stage clin­i­cal drug can­di­dates, in­clud­ing two pro­tein de­graders for B-cell ma­lig­nan­cies. Nurix’s shares $NRIX jumped by around 11% in the past month af­ter the com­pa­ny an­nounced re­search deal ex­ten­sions with both Gilead and Sanofi, though the stock fell about 6% Fri­day morn­ing. — Lei Lei Wu

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER